bamlanivimab: Clinical Trials

15 trials of bamlanivimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 terminated, 2 unknown, 1 no longer available. 5 Phase 2, 5 Phase 3, 3 Phase 4, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 4, Unknown 1
Phase 35Completed 5
Phase 43Terminated 2, Unknown 1
Phase 12Completed 2

Follow bamlanivimab: new trials by email Literature Review of bamlanivimab trials Research Report on bamlanivimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
Bamlanivimab, Bamlanivimab and Etesevimab Drug Combination, Casirivimab and Imdevimab Drug Combination - COVID-19
CompletedUniversity of Milano Bicocca2512021-10-142025-03-30
A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19
Bamlanivimab, Standard of Care - Covid19
Phase 4UnknownFraser Health5762021-03-172021-08-26
Treatment of Nosocomial COVID-19
Anti-SARS-CoV-2 mAb - Covid19, Nosocomial Infection
Phase 4TerminatedUniversity of Calgary462021-02-122023-04-19
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Bamlanivimab - COVID-19
Phase 2CompletedEli Lilly and Company1092021-02-012021-11-16
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
bamlanivimab - Covid19
Phase 4TerminatedDaniel Griffin1392021-01-042022-03-18
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB - Covid19
Phase 2UnknownSohail Rao10002020-11-202022-03-29
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Bamlanivimab, Etesevimab, Placebo - COVID-19
Phase 2CompletedEli Lilly and Company17552020-10-292022-07-01
A Study of LY3819253 (LY-CoV555) in Healthy Participants
LY3819253, Placebo - Healthy
Phase 1CompletedEli Lilly and Company252020-09-022021-12-06
ACTIV-2: A Study for Outpatients With COVID-19
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19
Phase 2 / Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)40442020-08-192024-08-02
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
LY3819253, Placebo, Remdesivir - COVID-19
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)3142020-08-052023-12-27
ACTIV-3: Therapeutics for Inpatients With COVID-19
LY3819253, Placebo, Remdesivir - Covid19
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)27532020-08-042023-08-25
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
Bamlanivimab, Placebo, Etesevimab - COVID-19, SARS-CoV2
Phase 3CompletedEli Lilly and Company11802020-08-022022-02-04
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
LY3819253, LY3832479, LY3853113 - COVID-19
Phase 2 / Phase 3CompletedEli Lilly and Company33072020-06-172024-04-11
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
LY3819253, Placebo - COVID-19
Phase 1CompletedEli Lilly and Company262020-05-282021-11-12
Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
Bamlanivimab - COVID-19
No longer availableEli Lilly and Company2023-10-02

Conditions studied

COVID-19 (14)  ·  Coronaviridae Infections (3)  ·  Coronavirus Infections (3)  ·  Nidovirales Infections (3)  ·  RNA Virus Infections (3)  ·  Severe Acute Respiratory Syndrome (3)  ·  Virus Diseases (3)  ·  Cross Infection (1)

Sponsors

Eli Lilly and Company (7)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Daniel Griffin (1)  ·  Fraser Health (1)  ·  Sohail Rao (1)  ·  University of Calgary (1)  ·  University of Milano Bicocca (1)

Countries

United States (11)  ·  Canada (3)  ·  Argentina (2)  ·  Denmark (2)  ·  Puerto Rico (2)  ·  Singapore (2)  ·  Spain (2)  ·  Brazil (1)  ·  Greece (1)  ·  Guatemala (1)  ·  Italy (1)  ·  Mexico (1)  ·  Nigeria (1)  ·  Philippines (1)  ·  Poland (1)

Top investigators

Alain Tremblay (1)  ·  Dan Griffin, MD, PHD (1)  ·  David Smith, MD, MAS (1)  ·  James Neaton, Prof. (1)  ·  Jens Lundgren, Prof. (1)  ·  Paolo Bonfanti, MD (1)  ·  Prof. James Neaton (1)  ·  Prof. Jens Lundgren (1)  ·  Robert Fowler (1)  ·  Sohail Rao, MD (1)  ·  Srinivas Murthy (1)

Results publications

PMID 34473343, PMID 35713300, PMID 34374951, PMID 33356051, PMID 33113295, PMID 33475701, PMID 34081073, PMID 34260849, PMID 34346827, PMID 34718468, PMID 34928698, PMID 34953520, PMID 34981077, PMID 35298440, PMID 35493124, PMID 35793677, PMID 35797235, PMID 35817072, PMID 35939810, PMID 35995785, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37329415, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 37948759, PMID 38291279, PMID 39018444, PMID 39028902, PMID 39230829, PMID 39922466, PMID 40262279, PMID 42148571